25 Results for "

FGFR1/2

" in MedChemExpress (MCE) Product Catalog:
Products (25)

25 Results for "FGFR1/2" in MCE Product Catalog:

  • Targets Recommended:
74
74 Publications Verification
Cat. No.: HY-50904
CAS No.: 656247-17-5
Synonyms: BIBF 1120
Target:  

PDGFR VEGFR FGFR

Research Areas:  

Cancer

Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
loading...
    loading...
74
74 Publications Verification
Cat. No.: HY-11106
CAS No.: 656247-18-6
Purity:  99.96%
Synonyms: BIBF 1120 esylate
Target:  

PDGFR VEGFR FGFR

Research Areas:  

Cancer

Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
loading...
    loading...
39
39 Cited Publications
Cat. No.: HY-18708
CAS No.: 1346242-81-6
Synonyms: JNJ-42756493
Target:  

FGFR Apoptosis

Research Areas:  

Cancer

Erdafitinib (JNJ-42756493) is a potent and orally available FGFR family inhibitor; inhibits FGFR1/2/3/4 with IC50s of 1.2, 2.5, 3.0 and 5.7 nM, respectively.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-19983
CAS No.: 1453208-66-6
Target:  

FGFR

Research Areas:  

Cancer

ASP5878 is an oral active inhibitor of FGFR 1, 2, 3, and 4, with IC50 values of 0.47 nM, 0.6 nM, 0.74 nM and 3.5 nM for FGFR 1, 2, 3, and 4 kinase activity. ASP5878 has potential antineoplastic activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-12965
CAS No.: 1265965-22-7
Purity:  99.44%
Target:  

FGFR c-Met/HGFR

Research Areas:  

Cancer

S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 values below 20 nM.
loading...
    loading...
Cat. No.: HY-165298
CAS No.: 2504949-52-2
Target:  

PROTACs FGFR ERK

Research Areas:  

Cancer

DGY-09-192 is a PROTAC FGFR1/2 degrader (FGFR1: DC50 = 4.35 nM; FGFR2: DC50 = 70 nM). DGY-09-192 preferentially degrades wild-type FGFR1/2 and multiple FGFR2 fusion proteins (including FGFR2-PHGDH and FGFR2-OPTN). DGY-09-192 suppresses downstream FGFR signaling (reducing phosphorylation of FRS2 Y196 and ERK1/2 T202/Y204) in vitro and vivo. DGY-09-192 can be used for the study of FGFR-driven cancers [1].
loading...
    loading...
Cat. No.: HY-50904S2
CAS No.: 1624587-87-6
Synonyms: BIBF 1120-d8
Nintedanib-d8 is deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
loading...
    loading...
Cat. No.: HY-145601
CAS No.: 2230490-29-4
Purity:  98.45%
Synonyms: TT 00420
Target:  

Aurora Kinase FGFR VEGFR

Research Areas:  

Cancer

Tinengotinib (TT00420) is an orally active, spectrally selective small molecule kinase inhibitor targeting Aurora A/B (IC50=1.2-3.3 nM), FGFR1/2/3 (IC50=1.5-3.5 nM), VEGFRs, JAK1/2 and CSF1R. Tinengotinib blocks Aurora kinase-mediated cell cycle progression (inducing G2/M arrest), inhibits FGFR/JNK-JUN signaling pathway and activates MEK/ERK-dependent apoptotic pathway. Tinengotinib has the activity of anti-tumor proliferation, inducing apoptosis, inhibiting angiogenesis and regulating tumor microenvironment. Tinengotinib can be used in the study of triple-negative breast cancer (TNBC), gallbladder cancer and tumor immune microenvironment [1] .
loading...
    loading...
Cat. No.: HY-15813
CAS No.: 1256152-35-8
Purity:  99.11%
Synonyms: FGFR irreversible inhibitor-1
Target:  

FGFR

Research Areas:  

Cancer

FIIN-1 is a potent, irreversible, selective FGFR inhibitor. FIIN-1 binds to FGFR1/2/3/4 and Flt1/4 with Kds of 2.8/6.9/5.4/120 nM and 32/120 nM respectively. The biochemical IC50s of FIIN-1 are 9.2, 6.2, 11.9, and 189 nM against FGFR1/2/3/4, respectively .
loading...
    loading...
Cat. No.: HY-50904S1
Synonyms: BIBF 1120-13C,d3
Nintedanib- 13C,d3 is the 13C- and deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
loading...
    loading...
Cat. No.: HY-18708R
CAS No.: 1346242-81-6
Synonyms: JNJ-42756493 (Standard)
Research Areas:  

Cancer

Erdafitinib (Standard) is the analytical standard of Erdafitinib. This product is intended for research and analytical applications. Erdafitinib (JNJ-42756493) is a potent and orally available FGFR family inhibitor; inhibits FGFR1/2/3/4 with IC50s of 1.2, 2.5, 3.0 and 5.7 nM, respectively.
loading...
    loading...
Cat. No.: HY-50904S
CAS No.: 1624587-84-3
Synonyms: BIBF 1120-d3
Nintedanib-d3 is the deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
loading...
    loading...
Cat. No.: HY-50904R
CAS No.: 656247-17-5
Synonyms: BIBF 1120 (Standard)
Research Areas:  

Cancer

Nintedanib (Standard) is the analytical standard of Nintedanib. This product is intended for research and analytical applications. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
loading...
    loading...
Cat. No.: HY-11106R
CAS No.: 656247-18-6
Synonyms: BIBF 1120 esylate (Standard)
Research Areas:  

Cancer

Nintedanib esylate (Standard) is the analytical standard of Nintedanib esylate. This product is intended for research and analytical applications. Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
loading...
    loading...
Cat. No.: HY-101466A
CAS No.: 1879965-80-6
Purity:  99.17%
Target:  

FGFR

Research Areas:  

Cancer

E7090 succinate is an orally available, selective and potent inhibitor of FGFR1, FGFR2 and FGFR3 tyrosine kinase activities, with IC50 values of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/2/3/4, respectively [1].
loading...
    loading...
Cat. No.: HY-159503A
CAS No.: 2847066-15-1
Synonyms: 3D185; HH185
Target:  

FGFR c-Fms

Research Areas:  

Cancer

Segigratinib hydrochloride (3D185) is a potent inhibitor of FGFR1/2/3 and CSF-1R; The IC50 values for FGFR1, FGFR2, FGFR3 and CSF-1R are 0.5, 1.3, 3.6 and 3.8 nM, respectively. Segigratinib hydrochloride has antitumor activity .
loading...
    loading...
Cat. No.: HY-161995
Research Areas:  

Cancer

FGFR1/VEGFR2-IN-2 (compound 6l) is a VEGFR2/FGFR1 dual inhibitor. The IC50 values for VEGFR2 and FGFR1 are 0.025 µM and 0.026 µM respectively, and for EGFR and PDGFR-β, the IC50 values are 0.106 µM and 0.077 µM. FGFR1/VEGFR2-IN-2 showes significant anti-cancer activity (GI=60.38%) on NCI-60 cell line, with an IC50 of 8.51 µM in T-47D cell line and anti-migration. FGFR1/VEGFR2-IN-2 acts to arrest cells in the G1 phase and promote apoptosis and necrosis; the IC50 for MCF-7 cell line exceeds 100 µM, and the IC50 for MDA-MB-231 is 69.17 µM, non-toxic to normal cells .
loading...
    loading...
Cat. No.: HY-131244
CAS No.: 2359662-39-6
Research Areas:  

Cancer

ALK-IN-9 (compound 40) is a potent ALK inhibitor. ALK-IN-9 inhibits cell proliferation with IC50s of <0.2 nM, <0.2 nM, 0.2 nM for Ba/F3-EML4-ALK, KM 12 (TPM3-TRKA), KG-l cell (OP2-FGFR1), respectively [1].
loading...
    loading...
Cat. No.: HY-60218
CAS No.: 114214-69-6
1-Boc-3-(hydroxymethyl)pyrrolidine is an intermediate. 1-Boc-3-(hydroxymethyl)pyrrolidine can be used to synthesize a FGFR1/2/3/4 inhibitor (Compound 2). 1-Boc-3-(hydroxymethyl)pyrrolidine can be used in cancer research .
loading...
    loading...
Cat. No.: HY-174154
CAS No.: 2640089-88-7
Target:  

FGFR

Research Areas:  

Cancer

INCB126503 is an orally activeM, selective FGFR2/3 Inhibitor with IC50 values of 70 nM (FGFR1), 2.1 nM (FGFR2), 1.2 nM (FGFR3), 0.92 nM (FGFR3-V555L), 0.85 nM (FGFR3-V555M) and 64 nM (FGFR4). INCB126503 suppresses FGFR signaling in vivo without causing hyperphosphatemia and shows antitumor efficacy in xenograft models harboring FGFR3 genetic alterations [1].
loading...
    loading...